Introduction {#S1}
============

The B vitamins constitute a group of water-soluble vitamins that play an important role in human health and cellular functions including growth and development ([@B1]). Vitamins B~6~ (pyridioxine), B~9~ (folic acid or folate), and B~12~ (cobalamin) have garnered extensive attention for their putative impacts on human health and diseases, ranging from cardiovascular disease and stroke to neurocognitive function and depression. Specifically, these B vitamins are critical for the maintenance of red blood cells ([@B2]), components of the nervous ([@B3]), and immune systems ([@B4]). Vitamin B~6~ deficiency, most common in the elderly, has been associated with conditions such as anemia, and neurological abnormalities such as depression, cognitive dysfunction, and neuropathy ([@B5]). Vitamin B~12~ deficiency can result in irreversible brain and nervous system damage and may be responsible for common symptoms such as fatigue and poor memory ([@B6], [@B7]). Folate (Vitamin B~9~) is critical for fetal growth and brain development, therefore folate deficiencies during pregnancy can result in neural tube defects in babies ([@B8]). In addition, Vitamins B~6~, B~9~, and B~12~ serve as important factors in homocysteine metabolism, with vitamin deficiencies resulting in increased levels of homocysteine ([@B9], [@B10]). Although controversial, elevated homocysteine levels are thought to increase risk for stroke ([@B11]) and vascular disease ([@B12], [@B13]).

Multiple factors contribute to variations in B vitamin levels in humans. A balanced diet is one approach to help minimize the detrimental effects of B vitamin deficiency. In January 1998, the United States Food and Drug Administration required manufacturers to fortify bread and grain products with folic acid to help prevent neural tube defects due to Vitamin B~9~ deficiency. These efforts have proven somewhat successful, with estimates from the 2002--2006 National Health and Nutrition Examination Survey (NHANES) reporting that most Americans are receiving adequate amounts of folate ([@B14]). In contrast, for Vitamin B~12~, data suggest that 5--15% of elderly patients are Vitamin B~12~ deficient, including data from the Centers for Disease Control and Prevention (CDC) and the NHANES study ([@B15]--[@B17]). Poor dietary intake, malabsorption from food, and genetic predisposition may all cause vitamin deficiencies. Polymorphisms in genes involved in B vitamin metabolism and processing, transport, absorption, and excretion are logical candidate genes that can influence B vitamin levels. Two such examples include human conditions Imerslund--Grasbeck syndrome (IGS) and megaloblastic anemia-1. IGS, a rare autosomal recessive disorder caused by mutations in cubilin (*CUBN*) and/or amnionless (*AMN*), was first characterized in the 1960s ([@B18], [@B19]) and results in megaloblastic anemia during childhood as a result of selective malabsorption of Vitamin B~12~. Additionally, genetic variants in the *CUBN* and *AMN* genes are responsible for the Finnish and Norwegian types of megaloblastic anemia-1, respectively ([@B20], [@B21]).

Understanding the genetic factors contributing to vitamin deficiencies offers opportunities for screening and identification of high-risk individuals before the presentation of any clinical manifestations. To date, several large-scale genome-wide association studies (GWAS) testing for association with Vitamin B~6~, B~12~, and folate have been published, resulting in more than 10 confirmed loci for these traits ([@B22]--[@B25]). Our group has conducted a GWAS for Vitamin B~6~, B~12~, and folate in an effort both to identify novel associations and replicate previously reported associations for these traits in a population of ischemic stroke patients from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial, an NIH-funded, multi-center, double-blind, randomized, controlled clinical trial designed to determine whether the daily intake of high-dose folic acid, Vitamins B~6~, and B~12~ reduced recurrent cerebral infarction and a combined vascular endpoint. Unlike the previous GWAS, the VISP study population represents an ethnically diverse population of older patients that present with elevated baseline homocysteine levels in the top quartile, have suffered a stroke, and thus, more closely represent the elderly population that is most prone to vitamin B deficiency and stroke.

Materials and Methods {#S2}
=====================

Subjects {#S2-1}
--------

The VISP trial was a multi-center, double-blind, randomized, and controlled clinical trial that enrolled patients aged 35 or older with homocysteine levels above the 25th percentile at screening and a non-disabling cerebral infarction (NDCI) within 120 days of randomization ([@B26], [@B27]). NDCI was defined as an ischemic brain infarction not due to embolism from a cardiac source, characterized by the sudden onset of a neurological deficit. The deficit must have persisted for at least 24 h, or if not, an infarction in the part of the brain corresponding to the symptoms must have been demonstrated by CT or MRI imaging. The trial was designed to determine if daily intake of a multivitamin tablet with high-dose folic acid, vitamin B~6~, and vitamin B~12~ reduced recurrent cerebral infarction and non-fatal myocardial infarction (MI) or mortality. Subjects were randomly assigned to receive daily doses of the high-dose formulation (*n* = 1,827), containing 25 mg pyridoxine (B~6~), 0.4 mg cobalamin (B~12~), and 2.5 mg folic acid; or the low-dose formulation (*n* = 1,853), containing 200 μg pyridoxine, 6 μg cobalamin, and 20 μg folic acid. Enrollment in VISP began in August 1997, and was completed in December 2002, with 3,680 participants enrolled from 55 clinic sites across the U.S. and Canada and one site in Scotland. All human research was approved by the relevant institutional review boards (IRBs), and conducted according to the Declaration of Helsinki. The VISP study protocol was approved by the IRBs of Wake Forest School of Medicine (coordinating center) and the University of North Carolina at Chapel Hill School of Medicine (statistical center). The local IRB for each of the individual recruiting sites approved the VISP protocol and all participants provided written, informed consent. VISP data analysis by the Genomics and Randomized Trial Network (GARNET) was approved by University of Virginia School of Medicine IRB.

Genome-wide association study in VISP {#S2-2}
-------------------------------------

A subset of VISP participants provided consent for inclusion in genetic studies. These participants were included in the GWAS component of VISP, supported by the National Human Genome Research Institute (NHGRI), Grant U01 HG005160, as part of the Genomics and Randomized Trials Network (GARNET); dbGaP Study Accession: phs000343.v3.p1. Samples were genotyped at the Johns Hopkins Center for Inherited Disease Research (CIDR), using the Illumina HumanOmni1-Quad_v1-0_B BeadChip (Illumina, San Diego, CA, USA). Individuals were excluded if they were unexpected duplicates or had gender discrepancies. A total of 2,100 individuals were included in the final genetic analyses; summary statistics are provided in Table [1](#T1){ref-type="table"}. These subjects consisted of 1,725 individuals of European descent, 258 individuals of African descent, and 117 individuals classified as others.

###### 

**Demographic summary statistics**.

  ------------------------------------- ---------------------
  Number of individuals (EA/AA/other)   2100 (1725/258/117)
  Age (years)                           
   Mean ± SD                            67.2 ± 10.8
   Range                                35--89
  \% Female participants (N)            37.4 (785)
  Current smokers (%)                   15.6
  Hypertension (%)                      71.0
  Diabetes mellitus (%)                 27.1
  **B Vitamin baseline measures**       
  Vitamin B~6~ (pm/mL) ± SD             42.45 ± 37.38
  Median                                33.49
  Vitamin B~12~ (pg/mL) ± SD            358.79 ± 181.91
  Median                                326
  Folate (ng/mL) ± SD                   25.86 ± 15.91
  Median                                22.67
  ------------------------------------- ---------------------

Biomarker measurements in VISP {#S2-3}
------------------------------

As previously described ([@B28]), basal levels of folate and Vitamin B~12~ were determined by the central laboratory at Oregon Regional Primate Research Center using single radioassays of folate and Vitamin B~12~ (Bio Rad Quantaphase II, Bio Rad Diagnostics, Hercules, CA, USA). For measures of Vitamin B~6~, EDTA plasma samples were analyzed using a commercially available method for plasma Pyridoxine 5′ Phosphate (ALPCO Inc Windham, NH, USA). The principle of the assay is as follows: ^3^H-tyrosine is decarboxylated by the vitamin B~6~ dependent enzyme tyrosine apodecarboxlase to ^3^H-tyramine. The activity of tyrosine apodecarboxlase is quantitatively dependent on the amount of PLP present in the reaction mixture. The ^3^H-tyramine thus produced is selectively extracted into the scintillation cocktail and can be measured by liquid scintillation counting. The excess ^3^H-tyrosine remains in the aqueous phase and is not measured.

Statistical analyses {#S2-4}
--------------------

Extensive quality control (QC) measures were performed, resulting in a total of 737,081 SNPs for analysis. QC measures included filtering SNPs based on missing call rate, Mendelian errors in control trios, deviation from Hardy--Weinberg equilibrium in controls, discordant calls in duplicate samples, sex differences in allele frequency or heterozygosity, and minor allele frequency (MAF) ([@B29]). Briefly, samples were clustered and genotypes determined using GenomeStudio (version 2010.2). For initial QC, SNPs meeting one or more of the following criteria were excluded: call rate \<85%, more than one replicate HapMap error, or cluster separation \<0.2. Genotype calls for individual chromosomes in samples with large chromosomal anomalies (\>10 Mb) or missing call rate \>5% were filtered out. Furthermore, samples with overall missing call rates \>5% and SNPs with call rates \<95% and Hardy--Weinberg *P*-values ≤10^−4^ were excluded from subsequent analyses. Multidimensional Scaling (MDS), utilizing the software KING ([@B30]), was performed to address confounders due to population substructure. Genome-wide association analyses for baseline quantitative measures of folate, and Vitamins B~12~ and B~6~ were performed using linear regression approaches, assuming an additive model, as implemented in PLINK; using age, sex, and the top 10 principal components as covariates. Inverse normal transformation was performed for each of the quantitative traits, prior to analysis. Inverse normal transformations were used to maintain ranks of the trait for each individual and minimize the impact of outliers while also allowing for sufficient power. Regression coefficients (beta), coefficient T-statistic (STAT), and *P*-values (asymptotic *P*-value for *T*-statistic) were calculated for the tested (minor) allele. The proportion of total variance explained (*h*^2^) was calculated as *h*^2^ = Beta^2^ × 2 × MAF × (1-MAF). Our GWAS scan results showed no evidence for inflation (GC lambda ≤ 1.013 in all scans.).

Results {#S3}
=======

We identified six associations that meet or exceed genome-wide significance (*P* ≤ 5 × 10^−08^; Table [2](#T2){ref-type="table"}; Figure S1 in Supplementary Material). Of these six associations, four were for Vitamin B~12~, while the remaining two were for Vitamin B~6~. The strongest evidence of association was observed for baseline Vitamin B~12~ (*P* = 1.76 × 10^−13^; beta = −0.22) with a non-synonymous SNP (nsSNP), located on chromosome 10 in the *CUBN* gene. Two additional *CUBN* intronic SNPs (Figure [1](#F1){ref-type="fig"}) were also strongly associated with Vitamin B~12~ (*P* = 2.92 × 10^−10^; beta = −0.19 and 4.11 × 10^−10^; beta = −0.18). A second nsSNP, located on chromosome 11 in the transcobalamin 1 (*TCN1*) gene (Figure [2](#F2){ref-type="fig"}), was also associated with baseline measures of Vitamin B~12~ (*P* = 5.14 × 10^−11^; beta = −0.29). The two genome-wide significant associations for Vitamin B~6~ measures (Figure [3](#F3){ref-type="fig"}) were located in the alkaline phosphatase (ALPL), liver/bone/kidney gene region (rs1697421; *P* = 7.06 × 10^−10^, beta = 0.173 and rs1780316; *P* = 2.25 × 10^−08^; beta = −0.325). Although not reaching the genome-wide significance threshold, our GWAS study has identified nine additional SNPs with suggestive (*P* ≤ 10^−07^) evidence of association, two for measures of Vitamin B~6~, six for measures of Vitamin B~12~, and one for measures of folate (Table [2](#T2){ref-type="table"}). A cluster of suggestive associations for Vitamin B~12~ was observed on chromosome 19, near the fucosyltransferase 2 (*FUT2)* gene. *P*-Values for the four associated SNPs ranged from 9.33 × 10^−07^ to 2.67 × 10^−07^. Individually, each associated SNP explains only a small amount of the variance (*h*^2^) for each trait (ranging from 0.009 to 0.021).

###### 

**Association results for SNPs with genome-wide (*P* ≤ 5 × 10^−08^) significance or suggestive evidence (*P* ≤ 10^−07^) for association**.

  SNP                                               Chromosome   Location (bp)[\*](#tfn1){ref-type="table-fn"}   Minor allele   Minor allele frequency   Beta     STAT     Variance explained   *P*-value (bold indicates *P* \< 5 × 10^−08^)   Gene (bold indicates novel finding)
  ------------------------------------------------- ------------ ----------------------------------------------- -------------- ------------------------ -------- -------- -------------------- ----------------------------------------------- -------------------------------------
  **VITAMIN B6**                                                                                                                                                                                                                                
  rs12118362                                        1            21644584                                        A              0.213                    0.172    5.228    0.010                1.91 × 10^−07^                                  ***NBPF3***
  rs1697421                                         1            21695879                                        T              0.471                    0.173    6.197    0.015                **7.06 × 10**^−^**^10^**                        *ALPL* (nearest)
  rs1780316                                         1            21762222                                        T              0.060                    −0.325   −5.616   0.012                **2.25 × 10**^−^**^08^**                        *ALPL*
  rs2267739                                         7            31103422                                        G              0.153                    −0.241   −4.910   0.015                9.92 × 10^−07^                                  ***ADCYAP1R1***
  **VITAMIN B12**                                                                                                                                                                                                                               
  rs7893634                                         10           17121145                                        A              0.415                    0.143    4.972    0.010                7.22 × 10^−07^                                  *CUBN*
  rs11254363                                        10           17170699                                        C              0.258                    0.155    4.918    0.009                9.48 × 10^−07^                                  *CUBN*
  rs12261966                                        10           17183006                                        A              0.311                    −0.185   −6.336   0.015                **2.92 × 10**^−^**^10^**                        *CUBN*
  rs1801222                                         10           17196157                                        A              0.316                    −0.218   −7.419   0.021                **1.76 × 10**^−^**^13^**                        *CUBN*
  rs11254375                                        10           17199198                                        G              0.312                    −0.184   −6.282   0.015                **4.11 × 10**^−^**^10^**                        *CUBN*
  rs34324219                                        11           59379954                                        A              0.104                    −0.292   −6.604   0.016                **5.14 × 10**^−^**^11^**                        *TCN1*
  SNP19-53897957[^⇓^](#tfn2){ref-type="table-fn"}   19           53897957                                        C              0.483                    0.142    5.162    0.010                2.69 × 10^−07^                                  *FUT2*
  rs516246                                          19           53897984                                        A              0.482                    0.142    5.164    0.010                2.67 × 10^−07^                                  *FUT2*
  rs492602                                          19           53898229                                        C              0.482                    0.143    5.193    0.010                2.29 × 10^−07^                                  *FUT2*
  rs2287921                                         19           53920084                                        C              0.471                    0.140    4.921    0.010                9.33 × 10^−07^                                  ***RASIP1***
  **FOLATE**                                                                                                                                                                                                                                    
  rs12611820                                        2            2462633                                         C              0.245                    −0.169   −4.913   0.011                9.75 × 10^−07^                                  ***MYT1L*** (nearest)

\* Based on hg18

^⇓^Corresponds to SNP rs516316

![**LocusZoom ([@B49]) association plot for single SNP associations with Vitamin B~12~ at the *CUBN* locus**. The SNP position and -LOG (*P*-value) are plotted on the *X* and *Y* axis, respectively.](fpubh-02-00112-g001){#F1}

![**LocusZoom association plot for single SNP associations with Vitamin B~12~ at the *TCN1* locus**. The SNP position and -LOG (*P*-value) are plotted on the *X* and *Y* axis, respectively.](fpubh-02-00112-g002){#F2}

![**LocusZoom association plot for single SNP associations with Vitamin B~6~ at the *ALPL* locus**. The SNP position and -LOG (*P*-value) are plotted on the *X* and *Y* axis, respectively.](fpubh-02-00112-g003){#F3}

In addition to our genome-wide analyses, we performed a look-up of 16 SNPs previously associated with measures of vitamin B~6~ (*n* = 1) ([@B22]), vitamin B~12~ (*n* = 12) ([@B22]--[@B24], [@B31]), and folate (*n* = 3) ([@B22], [@B23], [@B25]). Of the 16 SNPs previously reported in the literature, genotype data were available for 10 of the reported SNPs, while surrogate SNPs in high linkage disequilibrium (LD) (*r*^2^ \> 0.9) or the most significant SNP within 100 kb of the reported SNP were reported for the remaining six SNPs. Accounting for multiple testing (*P* = 0.05/16), five of the 16 SNPs, located in *ALPL, MS4A3, TCN1, CUBN*, and *FUT2*, were successfully replicated (*P* ≤ 0.003) in our study (Table [3](#T3){ref-type="table"}; Table S1 in Supplementary Material). For comparison, association results for the untransformed B vitamin measures are reported in Table S2 in Supplementary Material.

###### 

**Significant associations of 16 previously reported associations of Vitamin B~6~, Vitamin B~12~, and folate**.

  SNP               Chromosome   Gene      Literature *P*-value   Reference   Surrogate SNP   VISP *P*-value
  ----------------- ------------ --------- ---------------------- ----------- --------------- ----------------
  **VITAMIN B6**                                                                              
  rs1256335         1            *ALPL*    1.40 × 10^−15^         ([@B22])    --              3.41 × 10^−05^
  **VITAMIN B12**                                                                             
  rs1801222         10           *CUBN*    2.87 × 10^−09^         ([@B22])    --              1.76 × 10^−13^
  rs526934          11           *TCN1*    2.25 × 10^−10^         ([@B22])    --              3.38 × 10^−06^
  rs2298585         11           *MS4A3*   2.64 × 10^−15^         ([@B24])    rs7929589       8.67 × 10^−04^
  rs1047781         19           *FUT2*    3.62 × 10^−36^         ([@B24])    rs516246        2.67 × 10^−07^

Discussion {#S4}
==========

We performed a GWAS for measures of Vitamin B~12~, Vitamin B~6~, and folate by evaluating 737,081 SNPs in 2,100 participants from the Vitamin Intervention for Stroke Prevention (VISP) clinical trial. We observed six associations that reached genome-wide significance (*P* ≤ 10^−08^), an additional nine SNPs with suggestive (*P* ≤ 10^−07^) evidence of association, while replicating five previously reported SNP associations. The most convincing associations were observed for measures of Vitamin B12 at the *CUBN* and *TCN1* loci and the *ALPL* locus for measures of Vitamin B6. Although we did not observe any genome-wide significant associations for folate, we did detect suggestive evidence for association (*P* = 9.75 × 10^−07^) near the *MYT1L* gene, located on chromosome 2. Interestingly, genetic variations at this locus have been associated with depression ([@B32]) and schizophrenia ([@B33]--[@B35]). This locus may help explain the recent data positively correlating serum folate levels with cognitive test scores in children ([@B36]); suggesting further evaluation of the effects of folate levels in the elderly are warranted.

The most robust associations for Vitamin B~12~ levels were observed at the *CUBN, FUT2*, and *TCN1* loci (Table [2](#T2){ref-type="table"}). A cluster of five SNPs spanning the *CUBN* gene provided evidence for association with Vitamin B~12~ measures (*P*-values ranging from 9.48 × 10^−07^ to 1.75 × 10^−13^). The most significantly associated SNP in this region, rs1801222, was a non-synonymous variant resulting in a missense mutation, Phenylalanine to Serine. These results were not surprising considering rs1801222 was previously associated with Vitamin B~12~ measures ([@B22]) and the protein expressed by *CUBN* forms a receptor complex responsible for Vitamin B~12~ internalization in the ileum ([@B37]). Furthermore, genetic variants in *CUBN* are responsible for the Finnish type of megaloblastic anemia-1 ([@B38]) in humans and more broadly for IGS in canines as well ([@B39], [@B40]). A second cluster of suggestive associations near *FUT2* gene were consistent with previously reported associations in this region ([@B24], [@B25], [@B41]).

A second missense mutation (rs34324219), located in the Vitamin B~12~ binding protein, *TCN1* gene was associated with baseline measures of Vitamin B~12~ (*P* = 5.148 × 10^−11^). The nsSNP, rs34324219, results in an Aspartic acid to Tyrosine substitution and represents the second most significant association in our study. In the same VISP population, our group previously detected associations between genetic variants of the related gene, *TCN2*, and recurrent stroke risk ([@B42]). Although *TCN1* is a logical candidate gene influencing Vitamin B~12~ measures in this region, associations with variants in the nearby (\~200 kb) *MS4A3* gene ([@B24]) suggest that multiple genes in this region may impact Vitamin B~12~ levels. In an attempt to replicate the associations observed in *MS4A3* by Lin et al. ([@B24]) (rs2298585), we detected modest evidence of association for the surrogate SNP, rs7929589 (*r*^2^ = 0.39; *P* = 8.67 × 10^−04^; Table [3](#T3){ref-type="table"}). The protein encoded by *MS4A3* has been proposed to function as a hematopoietic cell cycle regulator ([@B43]), another potential link to the anemia observed in individuals with Vitamin B~12~ deficiency ([@B44]).

For measures of Vitamin B~6~, associations at the ALPL locus were most robust. Two variants at this locus reached genome-wide significance (rs1697421; *P* = 7.06 × 10^−10^ and rs1780316; *P* = 2.25 × 10^−08^). GWAS associations for variants near *ALPL* have been reported for Vitamin B~6~ ([@B22]). In addition, this region also harbors GWAS associations with traits ranging from TNFα response in patients with rheumatoid arthritis ([@B45]) to hematologic traits ([@B46]). While the physiological function of ALPLs are unknown, and no direct correlations have been made between *ALPL* variants and cognitive function, tissue non-specific ALPL is increased in Alzheimer's disease patients ([@B47]). Furthermore, Alzheimer's disease patients have an increased risk of suffering a stroke ([@B48]).

The data were collected as part of a randomized clinical trial is a systematic and standardized fashion, which is a major strength of the study. VISP used centralized laboratory analysis on all samples that complied with strict quality standards. The study population all had ischemic stroke and had elevated measures of serum homocysteine, which might limit generalizability. However, we replicated a substantial proportion of the previously identified genetic variants from studies using a more "general population." All participants in the VISP clinical trial were 35 years of age or older and suffered a stroke within 120 days of enrollment. This study population also represents an older group of individuals (mean age 67.2 years) that is most prone to vitamin deficiency and subsequent public health concerns including dementia and stroke. We are unable to make any comparisons in normal, healthy individuals, or assess the relation of such associations on stroke risk and other vascular disorders; however, collectively, our finding may provide some insight into the genetic factors influencing measures of B vitamins, in a vulnerable population. Although some dietary measures were collected as part of the VISP trial, we were not able to incorporate dietary "exposure" as a covariate in our analyses. Thus, we cannot identify gene by environmental interactions.

In summary, we performed a GWAS for measures of Vitamin B~6~, B~12~, and folate observing six genome-wide significant associations, nine suggestive associations, and successfully replicating 5 of 16 SNPs previously reported in the literature. Our study is the first of its kind evaluating genetic contributors for measurements of B vitamins in a stroke population. Additionally, this knowledge could lead to genetic screening approaches, which could identify pre-symptomatic individuals that could benefit from interventions such as enhanced vitamin supplementation prior to clinical manifestations.
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